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Abstract
Background: Vernakalant is a new, safe and effective drug used intravenously, which has 
proved to be more rapid in converting recent onset atrial fibrillation (AF) to sinus rhythm com-
pared to placebo, amiodarone, propafenone, and flecainide in clinical studies. Until now no 
study has been conducted comparing the perception of state of health in patients who received 
vernakalant versus propafenone or flecainide for conversion of recent-onset AF. The aim of our 
study is to compare the change of perception of state of health from screening to hour 2 in pa-
tients treated with vernakalant and propafenone or flecainide for conversion of recent-onset AF.
Methods: Eighty hemodynamically stable patients with recent onset AF without structural 
heart disease were prospectively included. A single oral dose of propafenone 600 mg was ad-
ministered to 30 patients, 30 patients received intravenous vernakalant and the remaining 
20 patients received a single oral dose of flecainide 300 mg. Clinical, laboratory variables and 
perception of state of health from screening to hour 2 treated with these drugs measured by the 
EQ-5 D quality-of-life assessments visual analog scale were recorded.
Results: Baseline characteristics were similar in the three groups. Treatment with vernaka-
lant resulted in a significantly greater improvement in patient perception of state of health at 
hour 2 compared with propafenone and flecainide. In the vernakalant group, a mean increase 
(from baseline) of 12.1 points was seen compared with a mean increase of 5.4 points in the 
propafenone group or 5.2 points in flecainide group (p < 0.01).
Conclusions: The change of perception of state of health from screening to hour 2 treated 
with vernakalant had a significantly statistical improvement compared with propafenone or 
flecainide for conversion recent-onset AF. (Cardiol J 2014; 21, 3: 304–308)
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Introduction
Recent-onset atrial fibrillation (AF) is a fre-
quent cause for presentation to the emergency 
department [1, 2]. Conversion of recent onset AF 
to sinus rhythm with antiarrhythmic drugs reduces 
the risk of hemodynamic instability, hospitaliza-
tions and atrial remodeling seen with persistent 
AF [3, 4].
Boriani et al. [5] compared oral loading dose of 
propafenone 600 mg with intravenous propafenone 
and placebo. At 8 h either intravenous or oral pro-
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pafenone were effective in almost two thirds of the 
patients with a statistical difference versus placebo.
Khan [6] showed that a single oral dose of fle-
cainide 300 mg had a similar time to conversion of 
AF to sinus rhythm to intravenous drugs class IC. 
This is the reason why an oral loading dose of 
propafenone 600 mg or a single dose of flecainide 
300 mg are used in our center as in other places 
around the world for conversion of recent onset 
AF in patients without structural heart disease.
Vernakalant is a new, safe and effective drug 
used intravenously for conversion AF and studied 
in patients with and without structural heart 
disease; even after cardiovascular surgery [7–10].
Vernakalant has proved to be more rapid 
in converting recent onset AF to sinus rhythm 
compared to placebo, amiodarone, propafenone, 
and flecainide [7, 9, 11, 12]. Until now no study 
has been conducted comparing the change of per-
ception of health state before and after in patients 
who received this new drug versus oral dose of 
propafenone or flecainide.
The aim of our study is to compare the change 
of perception of state of health from screening to 
hour 2 in patients treated with vernakalant and 
propafenone or flecainide for conversion of recent-
-onset AF.
Methods
This is a sequential study in which patients 
were included in three periods, one for each drug.
From 1 July to 30 October 2012, 30 patients 
were prospectively and consecutively included, 
hemodynamically stable with symptomatic recent 
onset AF (lasting less than 48 h) without structural 
heart disease underwent pharmacological cardio-
version and received an initial intravenous dose 
of vernakalant, 3.0 mg/kg over 10 min, followed 
by a 15 min observation period and, if conversion 
to sinus rhythm did not occur, a second 10 min 
infusion of vernakalant at a dose of 2 mg/kg was 
administered.
From 1 November 2012 to 31 January 2013, 
20 patients were prospectively and consecutively 
included and received a single oral dose of flecai-
nide 300 mg.
From 1 February to 30 April 2013, 30 patients 
were prospectively and consecutively included 
and received an oral loading dose of propafenone 
600 mg.
All patients received the pharmacological 
cardioversion. If patients persisted with AF af-
ter pharmacological cardioversion, the electrical 
cardioversion was done at 2 h after intravenous 
vernakalant or at 8 h after oral dose of propafenone 
or flecainide.
Inclusion criteria: Patients > 18 years old, 
with AF lasting less than 48 h and documented 
by electrocardiogram, weight between 45 kg and 
136 kg, systolic blood pressure > 90 mm Hg and 
< 160 mm Hg and diastolic blood pressure < 95 mm Hg.
Exclusion criteria: Pregnancy, atrial flutter, 
sinus node disease, QRS duration longer than 
140 ms in non-paced beats, QT interval > 440 ms, 
heart failure or acute coronary syndrome.
Clinical, laboratory and electrocardiographic 
variables were recorded. All the patients had con-
tinuous electrocardiographic monitoring. Color 
Doppler echocardiography with measurement of 
structural and functional parameters were perfor-
med to all the patients.
Primary outcome measure: The change 
of perception of state of health from screening to 
hour 2 in patients treated with vernakalant and 
propafenone or flecainide for conversion of recent-
-onset AF.
Adverse events: Death, sustained hypo-
tension (systolic blood pressure ≤ 90 mm Hg), 
bradycardia < 40 bpm, QT interval > 440 ms, 
ventricular arrhythmia (≥ triplets), or any other 
event that required or prolonged hospitalization 
were considered adverse events. Other events not 
meeting the criteria of seriousness, taste disorders, 
cough, nausea or dizziness were not considered 
serious adverse events.
The patients will receive anticoagulation 
therapy after discharge according the recom-
mendation of CHA2DS2-VASc score, but without 
antiarrhythmics drugs.
Follow-up: Follow-up visits were scheduled 
7 days after the index event to evaluate presence 
of symptoms and maintenance of sinus rhythm.
Statistical analysis
All calculations were performed using Statistix 
8.0 software package. Continuous variables were 
expressed as median with the corresponding inter-
quartile range (IQR) (p25–p75) and were compared 
using the Mann-Whitney test. Rates were expres-
sed as percentages and were compared using the 
c2 test with Fisher’s correction, if applicable. Time 
taken for conversion to sinus rhythm was illustra-
ted on a graph using the Kaplan-Meier method. 
The change of perception of state of health from 
screening to hour 2 was measured by the EQ-5D 
quality-of-life assessments visual analog scale, which 
has the Argentine valuation [13]. This inve- 
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stigation was in accordance with the Declaration of 
Helsinki. The protocol was reviewed and approved 
by an institutional review board or ethics commit-
tee at Instituto Cardiovascular de Buenos Aires, 
and written informed consent was obtained from 
the patients.
Results
Eighty patients were included; median age was 
63 years (54–69.5) and 67.5% were men.
No significant differences were found between 
the baseline characteristics and previous events 
of AF, invasive procedures and medication in the 
three groups (Tables 1, 2).
Time to conversion to sinus rhythm was 
11 min in the vernakalant group vs. 159 min (IQR 
125–325) in the propafenone group, and 167 min 
(IQR 130–315) in flecainide group (p < 0.01) 
(Fig. 1).
Conversion rate was of 83% in the propafe-
none group, 80% in the flecainide group at 8 h, 
and 91% in the vernakalant group at 2 h; yet, this 
difference was not statistically significant at 8 h 
(p = NS) (Fig. 1).
The stay length in emergency care section was 
246 min (IQR 190–280) in the vernakalant group vs. 
420 min (IQR 342–741) in the propafenone group, 
and 400 min (IQR 334–725) in flecainide group 
(p < 0.01) (Fig. 2).
Table 1. Baseline characteristics.
Variable Propafenone Vernakalant Flecainide
Male gender 60% 60% 70%
Age [years] 62 (54–66) 67 (56–69.5) 66 (55–69)
Body mass index [kg/m2] 26 (24–29) 27 (25–29.2) 26 (23–28)
Systolic blood pressure [mm Hg] 130 (120–142) 127 (121.5–130) 129 (119–135)
Diastolic blood pressure [mm Hg] 72 (67.7–81.5) 75 (69–80) 73 (67–75)
Cardiovascular risk factors:
Diabetes 20% 20% 30%
Hypertension 40% 30% 50%
Current or former smokers 60% 50% 70%
Dyslipidemia 60% 50% 70%
Thyroid disorders 10% 10% 20%
Rate ventricular response per min 154 (147–161) 161 (152–166) 163 (149–162)
Table 2. History of atrial fibrillation (AF) and medication.
Variable Propafenone Vernakalant Flecainide
Previous AF 10% 20% 10%
Previous AF ablation 10% 10% 20%
Previous treatment:
Beta-blockers 20% 30% 20%
Calcium channel blockers 0% 10% 0%
Propafenone/Flecainide 5% 0% 0%
Amiodarone 0% 10% 0%
Anticoagulation 0% 10% 10%
CHA2DS2-VASc score:
0 30% 20% 40%
1 40% 40% 40%
2 10% 30% 20%
3 20% 10% 0%
4 0% 0% 0%
5 0% 0% 0%
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Treatment with vernakalant resulted in 
a significantly greater improvement in patients’ per-
ception of state of health (as measured by the EQ-5D 
quality-of-life assessment visual analog scale) at hour 
2 compared with propafenone and flecainide. In the 
vernakalant group, a mean increase (from baseline) 
of 12.1 points was seen compared with a mean 
increase of 5.4 points in the propafenone group or 
5.2 points in flecainide group (p < 0.01).
No adverse events were reported.
After 1-week follow-up, all patients who had 
reverted remained in sinus rhythm. No late adverse 
events were reported.
Discussion
Several studies have demonstrated the effica-
cy of oral propafenone for conversion of recent on-
set AF to sinus rhythm [5]. Other studies showed 
that oral flecainide has a similar time to conversion 
to intravenous propafenone and flecainide [6].
Vernakalant is a novel, relatively atrial-se-
lective antiarrhythmic agent that is used intrave-
nously, prolongs the atrial refractory period but 
has little effect on ventricular repolarization. It is 
a multi-ion channel blocker blocking early-activa-
ting potassium channels combined with concentra-
tion-, voltage- and frequency-dependent blockade 
of sodium channels [7].
Vernakalant has a rapid distribution and onset 
of action with a mean half-life elimination of 3 h. 
Plasma concentrations decline approximately 50% 
in 10 min. Restoration of sinus rhythm occurs 
within 90 min in 50% of cases [7–10].
Vernakalant produced a rapid conversion 
according to the results of the CRAFT study [7] 
(vs. placebo) or AVRO study [9] (vs. amiodarone). 
There are two studies which showed that verna-
kalant is faster in conversion of recent-onset AF 
than propafenone and flecainide [11, 12]. 
There are no other studies designed to com-
pare the change of state of health in patients who 
were treated with vernakalant vs. propafenone 
and flecainide.
Our study is the first clinical investigation 
which analyzed the change of perception of state of 
health as a primary outcome and showed that ver-
nakalant had a significantly statistical improvement 
compared with propafenone and flecainide group.
The only study which compared the change 
of perception of state of health with vernaklant 
as a secondary outcome was the AVRO study [7], 
which compared vernakalant vs. amiodarone. In 
this trial the change of perception of state of health 
was better in vernaklant group compared with 
amiodarone group and the results of our study are 
similar to this one [7]. 
We suppose that there is a very strong rela-
tionship between the short time to conversion 
of AF to sinus rhythm and the better change 
of perception of state of health in vernakalant 
group. 
We believe that we need new clinical rando-
mized trials with more patients in this population 
to be able to reach the certainty that these results 
are able to extrapolate to the daily practice.
Figure 2. Length of stay in an emergency care section.
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Figure 1. Time to conversion of atrial fibrillation to sinus 
rhythm.
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Limitations of the study
Not to be a randomized trial is the most impor-
tant limitation of this study. The sample size may 
underestimate the differences between the groups. 
A larger sample size could produce statistically 
significant differences in the time to conversion 
and hospital stay length in the vernakalant group.
Conclusions
The change of perception of state of health 
from screening to hour 2 treated with vernakalant 
had a significantly statistical improvement compa-
red with propafenone or flecainide for conversion 
recent-onset AF.
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